Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 237   

Articles published

SNY 47.65 +0.34 (0.72%)
price chart
Sanofi SA (SNY) Pipeline Deserves More Credit, Says Citi
Citigroup Inc (NYSE:C), which remains neutral on Sanofi SA (ADR) (NYSE:SNY) stock, thinks that the company's pipeline deserves more credit despite the challenges its diabetes portfolio is currently facing.
AbbVie Inc (ABBV), Celgene Corporation (CELG), Sanofi SA (ADR) (SNY ...  StockWise Daily
Hot Alert: Sanofi SA (NYSE:SNY), Windstream Holdings (NASDAQ:WIN ...  Property Mentor
Related articles »  
Sanofi SA (SNY), Regeneron Pharmaceuticals (REGN) Eczema Drug Gets FDA ...
Sanofi SA (ADR) (NYSE:SNY) and its US-based partner Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) jointly developed experimental drug dupilumab has been granted breakthrough therapy designation by the US Food and Drug Administration for use ...
Sanofi (SNY) Expects $37.6 Billion Revenues From New Drugs
Sanofi SA (ADR) (NYSE:SNY), which has recently been in the limelight for the much publicized ousting of its former CEO Christopher Viehbacher, expressed confidence in its drug pipeline in a statement today.
Sanofi SA (SNY) Seeks Pharma Big Guns To Replace Ousted CEO
Sanofi SA (ADR) (NYSE:SNY) is said to have started approaching big names in the pharmaceutical industry to fill in the position of ousted CEO Chris Viehbacher.
Related articles »  
Sanofi SA (SNY) Stock On A Decline Since Ousting Of CEO Chris Viehbacher
Shares of Sanofi SA (ADR) (SNY) continue their downward journey since Chris Viehbacher was ousted from his position as CEO late October by the company's board of directors in the coup led by Chairman Serge Weinberg.
Related articles »  
Sanofi Fires CEO Following Clash With Board
Sanofi SA (ADR) (SNY) announced today that the company's board has decided to oust Chief Executive Officer Christopher Viehbacher, finally putting the rumors to rest.
Related articles »  
4 Red-Hot Healthcare Stocks: Sanofi SA (ADR) (NYSE:SNY), Salix ...
Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) made noteworthy gains on Tuesday after reporting positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with ...
Related articles »  
Buzz Stocks: Orbital Sciences Corp, Sanofi SA (ADR), and American Realty ...
Futures are little changed this morning, as investors await this afternoon's policy statement from the Federal Open Market Committee (FOMC).
Dark Clouds Hover Over Sanofi SA (ADR) (NYSE:SNY) and Twitter Inc (NYSE ...  Markets Emerging
Healthcare Stocks with Major Changes- Sanofi SA (ADR) (NYSE:SNY), Eli Lilly ...  StreetWise Report
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Dengue Outbreak Hits China; Sanofi In Lead For Cure
(ADR) (FUJIY) to step forward with their respective anti-Ebola treatment therapies. The Ebola outbreak has claimed about 3,500 lives as of October 8. This might have brought out the pharmaceutical industry's human side.
Related articles »